Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 20/20 | 0.61 |
| ▸ | JAK2 | O60674 | 17/20 | 0.61 |
| ▸ | JAK1 | P23458 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30343653 | 1.00 | NTRK1 (0.61) | NTRK1JAK2JAK1 | |
| SCHEMBL25560865 | 0.90 | NTRK1 (0.57) | NTRK1JAK2 | |
| SCHEMBL24030320 | 0.90 | NTRK1 (0.57) | NTRK1JAK2 | |
| SCHEMBL30151411 | 0.89 | NTRK1 (0.58) | NTRK1JAK2JAK1 | |
| SCHEMBL25180661 | 0.89 | NTRK1 (0.58) | NTRK1JAK2JAK1 | |
| SCHEMBL25907329 | 0.88 | NTRK1 (0.63) | NTRK1JAK2JAK1 | |
| SCHEMBL25181138 | 0.88 | NTRK1 (0.58) | NTRK1JAK2 | |
| SCHEMBL24030442 | 0.84 | NTRK1 (0.65) | NTRK1JAK2JAK1 | |
| SCHEMBL24030323 | 0.83 | NTRK1 (0.58) | NTRK1JAK2JAK1 | |
| SCHEMBL24168874 | 0.80 | NTRK1 (0.60) | NTRK1JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD (CN) | 2023-07-20 | — | — | US | disclosed |
| WO-2023083362-A1 | DRUG FOR TREATING TUMORS | 石药集团中奇制药技术（石家庄）有限公司 | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230227460-A1 | FUSED AZA-HETEROCYCLIC AMIDE COMPOUND AND USE THEREOF | ROS1, ALK, ROR1 | NTRK1 7/4885JAK2 380/4885JAK1 88/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.